Positron Stock Drops 4.7%, Analysts Recommend Other Buys

Shares of the medical imaging company Positron fell over 4% on Thursday, prompting questions about whether investors should sell.

Apr. 10, 2026 at 6:08am

Got story updates? Submit your updates here. ›

A high-contrast, cinematic close-up of various industrial financial machinery and equipment, representing the complex systems and infrastructure underlying stock market activity.A dramatic, high-contrast close-up of the complex financial machinery and infrastructure that powers the stock market, hinting at the unseen forces driving stock price fluctuations.Niagara Falls Today

Positron Corporation (OTCMKTS:POSC), a nuclear medicine healthcare company specializing in cardiac positron emission tomography (PET) imaging, saw its stock price drop 4.7% on Thursday, trading as low as $1.80 per share before closing at $1.81. Trading volume declined 6% from the average session. The company reported a loss in its latest quarterly earnings.

Why it matters

Positron's stock performance and financial results are closely watched by investors in the medical imaging and diagnostics industry. The company's PET scanners and services enable healthcare providers to accurately diagnose cardiac disease, but the stock's recent decline may signal concerns about the company's outlook.

The details

Positron's stock has a 50-day simple moving average of $2.03 and a 200-day simple moving average of $1.72. The company has a market cap of $59.46 million, a price-to-earnings ratio of -22.63, and a beta of 0.11.

  • Positron reported its latest quarterly earnings on March 31, 2026.
  • The stock price fell 4.7% on April 10, 2026.

The players

Positron Corporation

A nuclear medicine healthcare company that specializes in cardiac positron emission tomography (PET) imaging in the United States.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Positron's future financial results and any updates on the company's business strategy and product development.

The takeaway

The drop in Positron's stock price, combined with the company's recent quarterly loss and the fact that top analysts are not recommending the stock, suggests that investors may want to consider other investment opportunities in the medical imaging and diagnostics space.